US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer.

Preeti Narayan,Asma Dilawari,Christy Osgood,Zhou Feng,Erik Bloomquist,William F Pierce,Samina Jafri,Shyam Kalavar,Marina Kondratovich,Prakash Jha,Soma Ghosh,Shenghui Tang,Richard Pazdur,Julia A Beaver,Laleh Amiri-Kordestani

Journal of clinical oncology : official journal of the American Society of Clinical Oncology（2023）

引用 3|浏览11

暂无评分

摘要

The approval of T-DXd in HER2-low metastatic breast cancer was based on statistically significant and clinically meaningful PFS and OS improvements observed in the DESTINY-Breast04 trial and represents the first approved therapy specifically for the treatment of HER2-low metastatic breast cancer.

查看译文

关键词

epidermal growth factor receptor,metastatic breast cancer,epidermal growth factor,fam-trastuzumab,deruxtecan-nxki

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要